newsfilter
← Latest News
Business Wire·

Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212

— Screening is Now Underway to Identify Pregnant Women at Higher Risk for HPA-1a Alloimmunization and FNAIT — Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances